40 results about "Retinal" patented technology

Provided herein are ophthalmic pharmaceutical compositions, including compositions containing a fixed dose combination of active agents that are suitable for topical delivery to the eye(s) of a subject. In embodiments, the ophthalmic pharmaceutical compositions contain a glucocorticoid receptor agonist and an intraocular pressure lowering agent. Also provided are methods of manufacturing ophthalmic pharmaceutical compositions of the disclosure. Further provided are methods involving coadministration of a glucocorticoid receptor agonist and an intraocular pressure lowering agent, such as in the treatment of a patient suffering from an ocular condition.

The present invention discloses a β-carotene-grape seed extract eye-care preparation for retinal protection, relating to functional health foods. The preparation comprises active components and food-acceptable excipients. In parts by weight, the active components include 1–4 parts lutein, 0.5 –2 parts meso-zeaxanthin, 2 – 6 parts β-carotene, 8 – 25 parts blueberry extract, 5 – 18 parts grape seed extract, 0.2–1 part L-ergothioneine, 0.5–3 parts saffron extract, and 1–5 parts phosphatidylserine. The excipients comprise a filler, disintegrant, binder, and lubricant, with a weight ratio of active components to excipients of 1:1 to 1:4. By combining these eight components at specific ratios, the invention achieves synergistic effects, protects retinal health, and reduces blue-light damage. Dual-phase microencapsulation based on solubility, together with standardized preparation steps, improves stability and utilization efficiency.

This invention relates to the field of traditional Chinese medicine (TCM) technology. The invention provides a TCM composition for treating glaucoma and its preparation method, comprising the following components in parts by weight: 18-28 parts of Cassia seed, 12-18 parts of Lycium fruit, 12-18 parts of Eriocaulon buergerianum, 10-15 parts of vinegar-processed Cyperus rotundus, 10-15 parts of mulberry leaf, 10-15 parts of Ligusticum chuanxiong, 8-12 parts of Polyporus umbellatus, 5-8 parts of Pueraria lobata, 5-8 parts of Akebia quinata, 3-5 parts of Curcuma longa, 3-5 parts of Indigo naturalis, and 2-4 parts of prepared licorice root. The TCM composition of this invention has a strong effect in lowering intraocular pressure, improving retinal blood supply, and preventing optic nerve atrophy caused by glaucoma; simultaneously, the processing method maximizes the retention of the active pharmaceutical ingredients. Furthermore, the technical solution of this invention achieves a dual improvement in efficacy and safety, and also reduces the recurrence rate and side effects.

We provide TRPC5 inhibitors for use in treating or reducing the risk of developing kidney disease, diabetic retinopathy, anxiety disorders, depression, or cancer. [Solution] Compounds according to formula (I) or (II), and pharmaceutical compositions containing them are disclosed. A therapeutic method using a compound of formula (I) or (II) to treat, for example, kidney disease is also disclosed. JPEG2026086459000081.jpg3992

Provided are methods for treating an ocular neovascular disease in an individual by reducing Auction of central subfoveal thickness (CST) or central retinal thickness (CRT), comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide comprising an amino acid sequence with at least about 95% identity to the amino acid sequence of SEQ ID NO: 35 and Ranked by AAV2 inverted terminal repeats (ITRs), and b) an AAV2 capsid protein comprising an amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to an AAV2 VP1 capsid protein.

The application provides a granulocyte-guided double-space semantic calibration clustering method for diabetic retinopathy, comprising the following steps: step 1, designing an independent encoder to extract view-specific features; step 2, performing view quality evaluation on the view-specific embedding features output by each independent encoder, and calculating the confidence weight of each view; step 3, realizing double-space collaborative semantic calibration in the feature space and the clustering space; step 4, dividing the lesion semantic unit of diabetic retinopathy through granulocyte pre-modeling, and screening an initial clustering center from high-confidence granulocytes; and step 5, dynamically adjusting the exploration, utilization strategy and clustering center update step length based on the granulocyte confidence, and combining the semantic calibration signal to realize adaptive clustering optimization. The method helps to improve the accuracy and consistency of the double-view image staging clustering of diabetic retinopathy, and significantly reduces the early lesion missed diagnosis rate and the medium-term staging confusion rate.

The present disclosure provides an ophthalmic formulation comprising: one or more pharmaceutically acceptable excipients; a pharmaceutically active compound capable of reducing the amount or deleterious effects of autoantibodies on the ocular surface, such as IgG; in particular, the present disclosure provides an ophthalmic formulation wherein the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular diseases that can cause symptoms of ocular discomfort, keratitis, dry eye disease, formation of symblepharon, shortening of the anterior chamber depth, lid margin / conjunctival keratinization, subconjunctival fibrosis, retinal gliosis and glaucoma.

The invention discloses eye drops for treating vascular hyperplasia of eyes and a preparation method of the eye drops, and belongs to the technical field of biological pharmacy. The eye drops comprise a recombinant human angiostatin protein, an endostatin protein and a pharmaceutically acceptable carrier, wherein the recombinant human angiostatin protein and the endostatin protein are used for preparing the eye drops. Experiments show that the eye drops show remarkable vascular inhibition activity in a chick embryo chorioallantoic membrane model and a diabetic rat retina hyperplasia model, and the two proteins are combined for use to achieve a synergistic effect; the invention provides a safe and effective new way for local treatment of ocular vascular hyperplasia diseases.

This disclosure relates, in general, to a method for improving adhesion between the vitreous humor and the retina.

The application provides an animal model of high-oxygen-induced retinal neovascular disease and a preparation method thereof. The method comprises the following steps: placing a mouse born for 3-7 days in an environment with an oxygen concentration of 75-85%, and maintaining for 10-30 days. The method can successfully induce a long-acting retinal neovascular disease model, has a high modeling rate, fewer complications, more persistent retinal neovascular lesions, and a model duration of 55 days. The animal model provides a more optimal model for exploring long-acting anti-retinal neovascular related drugs.

The present invention relates to a composition for inhibiting angiogenesis containing yohimbine, and more specifically, to a pharmaceutical preparation and a functional food containing a composition capable of exhibiting preventive, improving, and therapeutic effects on angiogenesis-related diseases such as hemangioma, vascular adhesion, neovascular glaucoma, diabetic retinopathy, macular degeneration, corneal disease caused by neovascularization, or telangiectasia by containing yohimbine capable of inhibiting PDGF-induced vascular smooth muscle cell proliferation and migration through the factor FOXO3a.

This invention provides an application of a tartary buckwheat antioxidant peptide as a PARP1 inhibitor. This tartary buckwheat antioxidant peptide (SEQ ID NO:1) is used to prepare a poly(ADP-ribose) polymerase 1 inhibitor, and is used to prepare a drug for preventing and / or improving diabetic retinopathy. The tartary buckwheat antioxidant peptide of this invention exerts multiple biological functions by inhibiting PARP1 / PAR: on the one hand, it reduces NAD... + On the one hand, it depletes nutrients, and on the other hand, it protects vascular endothelial function by inhibiting angiogenesis. This buckwheat antioxidant peptide can be used as a drug to prevent and / or improve diabetic retinopathy.

A gene therapy drug for treating X-linked retinoschisis. The drug comprises a gene expression cassette expressing the retinoschisis protein (RS1 protein), enabling high-level expression of RS1 protein. By constructing a novel AAV viral vector, the RS1 protein is delivered into target cells. This effectively compensates for X-linked retinoschisis and related eye diseases caused by RS1 gene mutations, fundamentally treating X-linked retinoschisis and its complications, and improving vision.

An ophthalmic treatment device for photobiomodulation of a retina comprising: a treatment light source producing a continuous wave or quasi- continuous wave output beam having a wavelength in the range of 600nm to 1000nm and a power in the range of 1mW to 500mW; a beam homogenizing module that homogenizes the output beam of the treatment light source; a beam shaping module that modifies the output beam profile to produce a treatment light beam with an annular light beam profile; and a beam delivery and viewing module that allows an Operator to observe and operate to deliver the treatment light beam to the treatment location on the retina with an intensity in the range of 1 mW / cm2 to 500mW / cm2.

A method is provided for treating a patient having a neovascular ocular disease.

A micronutrient composition for infants and children from 6 months of age, characterized in that it is a liquid oral formulation containing the following main active ingredients: microencapsulated lutein, microencapsulated zeaxanthin, proanthocyanidins, anthocyanins, taurine, zinc, vitamin A and vitamin E, wherein the composition serves to support healthy retinal development in infants, to relieve visual fatigue and to build an antioxidant defense system in the eye.

Provided are methods for treating patients with type 1 diabetes, wherein the patient has new onset type 1 diabetes no more than eight months before starting treatment, and has not previously received an immunomodulatory agent. Also provided are methods for improving cell health in a patient having type 1 diabetes. Also provided are methods for preserving residual C-peptide in a patient having type 1 diabetes. The methods comprise administering an effective amount of a pharmaceutical therapy that comprises eflornithine while the patient is maintained on a low polyamine diet, wherein the method prevents, delays, decreases the likelihood of, or decreases the severity of diabetic ketoacidosis severe hypoglycemia, progression of diabetic nephropathy and retinopathy.

Methods of treating anterior or vitreous chamber ocular diseases by administering ophthalmic pharmaceutical compositions of roflumilast topically to the ocular surface of the eye of a patient. The met

This invention provides the application of guaijaverin in the prevention and / or treatment of diabetic retinopathy, belonging to the field of biopharmaceutical manufacturing technology. The application of guaijaverin in the prevention and / or treatment of diabetic retinopathy is described. This invention verifies the efficacy of guaijaverin by constructing an in vitro model of high-glucose damage in human retinal microvascular endothelial cells. Guaijaverin significantly improves high-glucose-induced abnormal cell proliferation and reduces membrane lipid peroxidation levels (using malondialdehyde content as an indicator). Further verification was conducted in a mouse model of high-glucose-induced retinopathy, clarifying that guaijaverin has a role in improving diabetic retinopathy. This invention creatively proposes that guaijaverin has a protective effect against diabetic retinopathy, protecting its preventive and / or therapeutic effects on diabetic retinopathy, and further protecting its development and application in products such as drugs for the prevention and / or treatment of diabetic retinopathy.

The application discloses a kind of polydopamine / drug nano composite particles and preparation method and application thereof.The polydopamine / drug nano composite particles in aqueous solution, using the synchronous process of alkaline drug molecule crystallization and dopamine oxidative polymerization, green synthesis nano drug.The polydopamine / drug nano composite particles of the application have: (1) high drug loading efficiency, simple preparation method; (2) have excellent active oxygen scavenging capacity; (3) response active oxygen controlled release drug; (4) the active oxygen of synthesis nano drug retains the activity of drug, such as nanofasudil nano drug can inhibit ROCK signal pathway; (5) good biocompatibility; can significantly reduce the ROS level in diabetic retinopathy model, reduce the expression of inflammatory factors, improve vascular leakage and inhibit neovascularization.The preparation process of the application is simple, the reaction condition is mild, and the biocompatibility is good, which provides a new nano drug delivery strategy for the treatment of diabetic retinopathy.

The present application belongs to the technical field of biology, and particularly relates to a construction of a retinal pigment degeneration disease model and application thereof. The construction method of the present application adopts a gene editing technology to make the 3rd exon of the CNGA1 gene of a non-human animal model to be mutated, and a retinal pigment degeneration disease model simulating a human c.253delC mutation can be constructed. The retinal pigment degeneration disease model can well simulate the disease caused by the mutation in the human body, and provides a good animal model for mechanism research and drug screening of the disease.

The present invention relates to a pharmaceutical composition and a food composition, for the prevention or treatment of degenerative retinal diseases, corneal epithelium wounds, and dry eye syndrome, comprising retinal organoid-derived exosomes.

The present disclosure provides an ophthalmic formulation comprising one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount or deleterious actions of autoantibodies on the ocular surface, such as IgG; In particular, the present disclosure provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular disease that can cause symptoms of ocular discomfort, keratitis, dry eye disease, symblepheron formation, fornix foreshortening, eyelid margin / conjunctival keratinization, subconjunctival fibrosis, retinal gliosis and glaucoma.

Methods for treating diseases of the anterior chamber or vitreous chamber of the eye by topical administration of ophthalmic pharmaceutical compositions containing roflumilast to the ocular surface of a patient. The methods involve the topical administration of ophthalmic pharmaceutical compositions containing roflumilast to the ocular surface of a patient three or four times daily at a higher concentration and with a higher frequency, thereby achieving a significant therapeutic effect on the anterior chamber and vitreous chamber, using dosage regimens with higher concentrations and a lower frequency of administration than other treatment regimens.

Provided are formulations and methods for treating patients having AMD, by inhibiting formation or growth of drusen, and / or reducing number and / or size of drusen, while maintaining or restoring ellipsoid zone area in a human eye.

Provided are formulations and methods for treating drusen and / or AMD, such that the risk of vitreous flare and lens opacity or lens haziness, e.g., cataract formation, is reduced or substantially eliminated.

The application relates to the technical field of medical devices, and discloses a prone device beneficial to retinal repositioning after fundus disease operation, which comprises a sliding clamping mechanism and a universal adjusting support mechanism, and the structure comprises a hemispherical shell capable of being fixedly installed on the surface of a fixing structure and internally provided with a hollow structure, a hollow sphere capable of rotating and installed in the hemispherical shell, and an arc-shaped fixing plate capable of being fixedly installed in the middle part of a horizontal sliding rod and arranged at the top of the hollow sphere. The prone device beneficial to retinal repositioning after fundus disease operation can slide and clamp the head of a patient, thereby realizing the fixation of the head of the patient. In addition, the device can adjust the angle of the head of the patient, the angle adjustment is an adjustment in a three-dimensional space, and the device has the characteristics of wide adjustment range, thereby improving the practicability of the device.